Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS (NCT07197944)
A Phase 3, Double-blind, Randomized, Parallel Group, Placebo-controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice Weekly, Followed by a Long-term, Open-label Safety Evaluation in Patients With Short Bowel Syndrome-intestinal Failure (SBS-IF)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data. Glepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848.
Who can join: Review the eligibility criteria below.
Location: The University of Chicago Medicine — Chicago, Illinois
Age range: 18 Years to 90 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (31 Sites)
Showing the first 25 of 31 sites.
- The University of Chicago Medicine — Chicago, Illinois
- Washington University Center for Advanced Medicine — St Louis, Missouri
- Lied Transplant Center at Nebraska Medical Center — Omaha, Nebraska
- New York Presbyterian Hospital-Columbia University Medical Center — New York, New York
- Vanderbilt University Medical Center — Nashville, Tennessee
- Universitätsklinikum AKH Wien — Vienna, State of Vienna
- Universitair Ziekenhuis (UZ) Leuven — Leuven,
- Rigshospitalet-Blegdamsvej 9 — Copenhagen,
- Helsingin Yliopistollinen Keskussairaala — Helsinki,
- AP-HP - Hôpital Beaujon — Clichy,
- Universitätsmedizin Rostock — Rostock, Mecklenburg-Vorpommern
- Eugastro Klinische Studien GmbH — Leipzig, Saxony
- Universitätsklinikum Aachen — Aachen,
- Charité - Universitätsmedizin Berlin — Berlin,
- Universitätsklinikum Bonn — Bonn,
- Asklepios Klinik St. Georg — Hamburg,
- Eszak-Pesti Centrumkorhaz -Honvedkorhaz- Podmaniczky utcai telephely — Budapest,
- Semmelweis Egyetem - Sebészeti, Transzplantációs és Gasztroenterológiai Klinika — Budapest,
- Dél-budai Centrumkórház Szent Imre Egyetemi Oktatókórház — Budapest,
- Fondazione Policlinico Universitario A. Gemelli IRCCS - PPDS — Rome, Lazio
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico — Milan,
- Azienda Ospedale - Università Padova — Padova,
- Radboud Universitair Medisch Centrum — Nijmegen, Gelderland
- Oslo Universitetssykehus HF, Ullevål — Oslo,
- Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi — Lodz, Lódzkie
📞 Contact the Study Coordinator
Phone: (773) 702-6921
Email: csemrad@medicine.bsd.uchicago.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Short Bowel Syndrome
- Registry for Participants With Short Bowel Syndrome — Lexington, Massachusetts
- Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS — Washington D.C., District of Columbia
- Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial — Washington D.C., District of Columbia
- Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome — Cleveland, Ohio
- Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. — Los Angeles, California
- A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome — Palo Alto, California
Explore by condition: All Short Bowel Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.